USA - NASDAQ:WBA - US9314271084 - Common Stock
The current stock price of WBA is 11.98 USD. In the past month the price increased by 3.01%. In the past year, price increased by 29.51%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| GRDN | GUARDIAN PHRMCY SERVICES-A | N/A | 2.00B | ||
| MGRX | MANGOCEUTICALS INC | N/A | 18.55M | ||
| SRXH | SRX HEALTH SOLUTIONS INC | N/A | 6.01M |
Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. The company is headquartered in Deerfield, Illinois and currently employs 193,000 full-time employees. The company went IPO on 2014-12-31. The Company’s segments include U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment includes the Walgreens business, which includes the operations of retail drug stores, health and wellness services, and specialty and home delivery pharmacy services, and its equity method investment in Cencora, Inc. The International segment consists of pharmacy-led health and beauty retail businesses outside the United States and a pharmaceutical wholesaling and distribution business in Germany. The pharmacy-led health and beauty retail businesses include Boots branded stores in the United Kingdom, the Republic of Ireland and Thailand, and the Benavides brand in Mexico. The firm's U.S. Healthcare segment is a consumer-centric, technology-enabled healthcare business that engages consumers through a personalized, omni-channel experience across the care journey.
WALGREENS BOOTS ALLIANCE INC
108 Wilmot Rd
Deerfield ILLINOIS 60015 US
CEO: Rosalind Brewer
Employees: 252500
Phone: 18473152500
Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. The company is headquartered in Deerfield, Illinois and currently employs 193,000 full-time employees. The company went IPO on 2014-12-31. The Company’s segments include U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment includes the Walgreens business, which includes the operations of retail drug stores, health and wellness services, and specialty and home delivery pharmacy services, and its equity method investment in Cencora, Inc. The International segment consists of pharmacy-led health and beauty retail businesses outside the United States and a pharmaceutical wholesaling and distribution business in Germany. The pharmacy-led health and beauty retail businesses include Boots branded stores in the United Kingdom, the Republic of Ireland and Thailand, and the Benavides brand in Mexico. The firm's U.S. Healthcare segment is a consumer-centric, technology-enabled healthcare business that engages consumers through a personalized, omni-channel experience across the care journey.
The current stock price of WBA is 11.98 USD. The price increased by 0.5% in the last trading session.
WBA does not pay a dividend.
WBA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
WBA stock is listed on the Nasdaq exchange.
The next ex-dividend date for WALGREENS BOOTS ALLIANCE INC (WBA) is November 18, 2024.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on WBA.
ChartMill assigns a technical rating of 10 / 10 to WBA. When comparing the yearly performance of all stocks, WBA is one of the better performing stocks in the market, outperforming 76.31% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to WBA. WBA has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months WBA reported a non-GAAP Earnings per Share(EPS) of 1.91. The EPS decreased by -39.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.07% | ||
| ROE | -87.68% | ||
| Debt/Equity | 1.09 |
11 analysts have analysed WBA and the average price target is 10.81 USD. This implies a price decrease of -9.75% is expected in the next year compared to the current price of 11.98.
For the next year, analysts expect an EPS growth of -38.04% and a revenue growth 6.29% for WBA